用克隆性造血风险评分(CHRS)预测CAR-T后治疗相关髓系肿瘤
研究在55例接受CD19靶向CAR-T细胞治疗的患者中评估克隆性造血,CAR-T前CHIP和CCUS分别占7%和33%,治疗后观察到3例治疗相关髓系肿瘤(2例MDS和1例AML)。仅基线CHRS中高值患者发生t-MN,其CAR-T后9个月内发生t-MN的风险增加两倍以上(OR 2.89,95%CI 1.98-4.19,P<0.001),CHRS能以良好特异性预测CAR-T后t-MN的发生。
要点
- 55例CD19 CAR-T患者中,CAR-T前CHIP占7%、CCUS占33%。
- 治疗后发生3例t-MN(2例MDS、1例AML),仅见于基线CHRS中高值患者。
- 基线CHRS中高值者CAR-T后9个月内t-MN风险增加两倍以上(OR 2.89,95%CI 1.98-4.19,P<0.001)。
核心结论
- CHRS能够以良好特异性预测CAR-T后治疗相关髓系肿瘤的发生。
- 仅基线CHRS中高值的患者发生了治疗相关髓系肿瘤。
研究设计与样本
- 研究纳入55例连续接受CD19靶向CAR-T细胞治疗的患者,检测CAR-T前克隆性造血。
- CHRS涵盖突变类型与VAF、单个DNMT3A突变、血细胞减少、年龄、红细胞分布宽度(RDW)和平均红细胞体积(MCV)。
主要发现
- CAR-T前CHIP占7%,CCUS占33%。
- CAR-T治疗后观察到3例治疗相关髓系肿瘤(2例MDS和1例AML)。
- 基线CHRS中高值患者CAR-T后9个月内发生t-MN的风险增加两倍以上(OR 2.89,95%CI 1.98-4.19,P<0.001)。
关键数值与推荐
- CHRS中高值患者CAR-T后9个月内t-MN的OR为2.89(95%CI 1.98-4.19,P<0.001)。
- CAR-T前CHIP占7%,CCUS占33%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clonal haematopoiesis risk score (CHRS) was proposed to predict the rate of progression from clonal haemopoiesis of indeterminate potential (CHIP)/clonal cytopenia with unknown significance (CCUS) to myeloid neoplasms in the general population. CHRS encompasses the type and VAF of the mutation, the presence of a single DNMT3A mutation, cytopenia, age, red cell distribution width (RDW) and mean corpuscular volume (MCV). We studied clonal haematopoiesis in a cohort of 55 consecutive patients treated with CD19-directed CAR-T cells: CHIP and CCUS were present in 7% and 33% of patients before CAR-T. Three therapy-related myeloid neoplasms (t-MN) were observed after treatment with CAR-T (2 MDS and 1 AML). Only patients with an intermediate-high baseline CHRS developed a t-MN. Patients with an intermediate-high CHRS had more than a twofold increased risk of developing a t-MN within the first 9 months after CAR-T (odds ratio 2.89, 95% C.I. 1.98-4.19, p < 0.001). Overall, CHRS was able to predict the occurrence of t-MN after CAR-T with good specificity.
引用
- Galli E, Rossi M, Pansini I, et al. Predicting therapy-related myeloid neoplasms after CAR-T with the Clonal Haematopoiesis Risk Score (CHRS). Br J Haematol. 2024. PMID: 39539012. doi:10.1111/bjh.19905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。